{"id":75173,"date":"2016-08-16T14:03:02","date_gmt":"2016-08-16T14:03:02","guid":{"rendered":"http:\/\/www.abnewswire.com\/pressreleases\/?p=75173"},"modified":"2016-08-16T14:03:02","modified_gmt":"2016-08-16T14:03:02","slug":"depressive-disorder-market-global-analysis-with-20162020-forecasts-research-report","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/depressive-disorder-market-global-analysis-with-20162020-forecasts-research-report_75173.html","title":{"rendered":"Depressive Disorder Market Global Analysis with 2016-2020 Forecasts Research Report"},"content":{"rendered":"
\"\"<\/a><\/p>\n
\n
“Market Research Reports and Industry Analysis”<\/div>\n<\/div>\n<\/div>\n
OrbisResearch.com has published \u201cGlobal Depressive Disorder Market: Industry Analysis & Outlook (2016-2020)\u201d market report to its research database. Key companies listed in the report are Pfizer Inc., AstraZeneca, Eli Lilly and Company, and Lund beck.<\/div>\n

Depression is a serious mood disorder, affecting the ability to think, feel, and handle situations like sleeping, eating, or working. It is a mood disorder that causes a persistent feeling of sadness and loss of interest. It builds up a very negative perspective in the way of thinking in every single thing and damages a person’s ability to see brighter versions of any situation in life. It is of various types like major depressive disorder (MDD), perinatal depression, psychotic depression, seasonal depression and bipolar depression.<\/p>\n

To be diagnosed with depression, the symptoms must be present for at least two weeks. It may require long-term treatment for years. There is no single cause of depression; it is likely an outcome from combinations of genetic, biochemical, environmental and physiological factors. There are several ways of treating depression depending upon each individual’s characteristics & symptoms. Most people feel better with medication, psychological counseling or both.<\/p>\n

The global depressive disorder market <\/a>is expected to grow and overcome falling revenues due to patent expiry with better innovative drugs and therapies. The US has highest depression disorder prevalence along with highest prevalence of bipolar depression & schizophrenia. With growing awareness and better access to medical facilities, the depressive disorder market is expected to grow worldwide, especially in Asia-Pacific region.<\/p>\n

Table of Contents:<\/strong>
1. Market Overview
2. Global Market
3. Regional Markets
4. Market Dynamics
5. Competitive Landscape
6. Company Profiles<\/p>\n

The key factors driving the growth of the depressive disorder market includes increased smoking prevalence, rising healthcare expenditure, growing female population, increasing spending on medicines and rising number of prescription drugs. However, there are certain factors hindering the growth of the market like patent expiry, severe side effects of drugs, and tough regulations. Major trends of the market include novel drug approvals, major drugs in pipeline, and growing public awareness.
The report offers an in-depth analysis of the “Global Depressive Disorder Market” segmented into global and regional markets. Competition is concentrated in the hands of few major pharmaceutical companies out of which Pfizer Inc., AstraZeneca, Eli Lilly and company, and Lundbeck have been covered in the report.<\/p>\n

Place a direct purchase order on this report at <\/strong>http:\/\/www.orbisresearch.com\/contact\/purchase\/102387<\/a>
<\/strong><\/p>\n

List of Charts<\/strong>
Types of Depression
Causes & Symptoms of Depression
Global Depressive Disorder Market by Value (2010-2015)
Global Depressive Disorder Market Forecast by Value (2016-2020)
Global Depressive Disorder Market by Region (2015)
Global Anti-Depressant Drug Market by Value (2010-2015)
Global Anti-Depressant Drug Market Forecast by Value (2016-2020)
Global Anti-Psychotic Drug Market by Value (2010-2015)
Global Anti-Psychotic Drug Market Forecast by Value (2016-2020)
The US Depressive Disorder Market Forecast by Value (2015-2020)
The US Mental Health Drug Prescription by Volume (2011-2015)
The US Depressive Disorder Patient Prevalence Forecast (2016-2020)
The US Bipolar Depression Patient Prevalence Forecast (2016-2020)
The US Bipolar Depression Addressable Population Forecast (2016-2020)
The US Schizophrenia Patient Prevalence Forecast (2016-2020)
The US Schizophrenia Addressable Population Forecast (2016-2020)
European Depression Disorder Market Forecast by Value (2015-2020)
European Bipolar Depression Patient Prevalence Forecast (2016-2020)
European Bipolar Depression Addressable Population Forecast (2016-2020)
European Schizophrenia Patient Prevalence Forecast (2016-2020)
European Schizophrenia Addressable Population Forecast (2016-2020)
China Anti-Depressant Drug Market by Value (2010-2015)
China Anti-Depressant Drug Market Forecast by Value (2016-2020)
China Anti-Psychotic Drug Market by Value (2010-2015)
China Anti-Psychotic Drug Market Forecast by Value (2016-2020)
Increasing Sales of Prescription Drugs (2010-2015)
Global Spending on Medicines (2010-2020E)
Total Spending on Medicines in the US (2010-2015)
Global Cigarette Consumption (1940-2015)
Global Healthcare Expenditure (2009-2015)
Global Female Population (2010-2015)
Global Depressive Disorder Market Revenue Comparison (2015)
Global Anti-Depressant Market Share by Drugs (2015)
Global Anti-Depressant Drug Revenue Comparison (2018)
Global Anti-Psychotic Market Share by Drugs (2015)
Global Anti-Psychotic Drug Revenue Comparison (2020)
Pfizer Inc. Revenue by Segment (2015)
Pfizer Inc. Revenue and Net Income (2012-2015)
AstraZeneca Revenue by Segment (2015)
AstraZeneca’s Revenue (2012-2015)
Eli Lilly Revenue Share by Segments (2015)
Eli Lilly Revenue and Net Income (2011-2015)
Lundbeck’s Key Therapeutic Areas (2015)
Lundbeck’s Revenue Share by Products (2015)
Lundbeck’s Revenue and Net Income (2011-2015)
Lundbeck’s Research & Development Expenses (2011-2015)<\/p>\n

Browse more reports on Pharmaceuticals Market at <\/strong>http:\/\/www.orbisresearch.com\/market-reports\/pharmaceuticals-and-healthcare\/pharmaceutical.html<\/a>
<\/strong><\/p>\n

About Us:<\/strong>
Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customised reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialisation. This helps our clients to map their needs and we produce the perfect required market research study for our clients.<\/p>\n

Media Contact<\/span>
Company Name:<\/strong> Orbis Research
Contact Person:<\/strong> Hector Costello
Email:<\/strong> sales@orbisresearch.com
Phone:<\/strong> +1 (214) 884-6817
Address:<\/strong>4144N Central Expressway, Suite 600
City:<\/strong> Dallas
State:<\/strong> Texas
Country:<\/strong> United States
Website:<\/strong> http:\/\/www.orbisresearch.com\/reports\/index\/global-depressive-disorder-market-industry-analysis-and-outlook-2016-2020<\/a><\/p>\n

<\/object><\/p>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

“Market Research Reports and Industry Analysis” OrbisResearch.com has published \u201cGlobal Depressive Disorder Market: Industry Analysis & Outlook (2016-2020)\u201d market report to its research database. Key companies listed in the report are Pfizer Inc., AstraZeneca, Eli Lilly and Company, and Lund … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":0,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401],"tags":[],"class_list":["post-75173","post","type-post","status-publish","format-standard","hentry","category-Business"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/75173","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=75173"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/75173\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=75173"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=75173"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=75173"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}